nach oben

Erschienen in:

15.02.2019 | Original Article

Preliminary report of microwave ablation for the primary papillary thyroid microcarcinoma: a large-cohort of 185 patients feasibility study

verfasst von: Deng-Ke Teng, He-Qun Li, Guo-Qing Sui, Yuan-Qiang Lin, Qiang Luo, Ping Fu, Jia-Rui Du, Chun-Xiang Jin, Hui Wang

Erschienen in: Endocrine | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To assess the safety and efficacy of microwave ablation (MWA) for primary papillary thyroid microcarcinoma (PTMC) with a large sample of 185 patients.

Methods

A total of 185 patients underwent MWA for 206 primary PTMC nodules. They received ultrasound follow-up at 1, 3, 6, and 12 months after MWA and every 6 months thereafter. Nodule volumes were calculated at each follow-up and compared with those before MWA. Additionally, the volume reduction rate (VRR) of the nodules was calculated. Patients’ thyroid functions were tested before and 1 month after MWA.

Results

The mean follow-up time of the 185 patients was 20.7 ± 8.8 months (range 12–36 months). During the follow-up period, the mean volume of the 206 nodules was 100.1 ± 92.9 mm³ (range 3.6–423.9) before MWA, which decreased to 2.2 ± 5.6 mm³ (range 0–20.3 mm³) after MWA (P = 0.000). The mean VRR of the nodules was 98.65 ± 3.60% after MWA (range 83.85–100%). One hundred and seventy four of 206 nodules (84.5%) were fully absorbed. Compared with the preoperative results, no significant variation in thyroid function was observed 1 month after MWA. Thirty-eight patients (20.5%) had different types of complications, ranging from minor to major. Five patients (2.7%) had hoarseness, 11 patients (5.9%) had bleeding, 21 patients (11.4%) had earache or toothache, and one patient had another lesion 1 month after MWA.

Conclusions

This preliminary study suggests that MWA is safe and effective in the treatment of primary PTMC and offers a new alternative for clinical treatment.

L.G. Morris, R.M. Tuttle, L. Davies, Changing Trends in the Incidence of Thyroid Cancer in the United States. JAMA Otolaryngol.-- Head Neck Surg. 142(7), 709–711 (2016). https://doi.org/10.1001/jamaoto.2016.0230 CrossRefPubMedPubMedCentral

B. Aschebrook-Kilfoy, R.B. Schechter, Y.C. Shih, E.L. Kaplan, B.C. Chiu, P. Angelos, R.H. Grogan, The clinical and economic burden of a sustained increase in thyroid cancer incidence. Cancer Epidemiol. Biomark. Prev. 22(7), 1252–1259 (2013). https://doi.org/10.1158/1055-9965.epi-13-0242 CrossRef

S. Vaccarella, S. Franceschi, F. Bray, C.P. Wild, M. Plummer, L. Dal Maso, Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N. Engl. J. Med. 375(7), 614–617 (2016). https://doi.org/10.1056/NEJMp1604412 CrossRefPubMed

Y. Ito, A. Miyauchi, H. Oda, Low-risk papillary microcarcinoma of the thyroid: A review of active surveillance trials. Eur. J. Surg. Oncol. (2017). https://doi.org/10.1016/j.ejso.2017.03.004

A. Griffin, J.P. Brito, M. Bahl, J.K. Hoang, Applying criteria of active surveillance to low-risk papillary thyroid cancer over a decade: how many surgeries and complications can be avoided? Thyroid 27(4), 518–523 (2017). https://doi.org/10.1089/thy.2016.0568 CrossRefPubMed

G.C. Haser, R.M. Tuttle, H.K. Su, E.E. Alon, D. Bergman, V. Bernet, E. Brett, R. Cobin, E.H. Dewey, G. Doherty, L.L. Dos Reis, J. Harris, J. Klopper, S.L. Lee, R.A. Levine, S.J. Lepore, I. Likhterov, M.A. Lupo, J. Machac, J.I. Mechanick, S. Mehra, M. Milas, L.A. Orloff, G. Randolph, T.A. Revenson, K.J. Roberts, D.S. Ross, M.E. Rowe, R.C. Smallridge, D. Terris, R.P. Tufano, M.L. Urken, Active surveillance for papillary thyroid microcarcinoma: new challenges and opportunities for the health care system. Endocr. Pract. 22(5), 602–611 (2016). https://doi.org/10.4158/ep151065.ra CrossRefPubMedPubMedCentral

H.G. Welch, G.M. Doherty, Saving thyroids - overtreatment of small papillary cancers. N. Engl. J. Med. 379(4), 310–312 (2018). https://doi.org/10.1056/NEJMp1804426 CrossRefPubMed

P. Liang, Y. Wang, X. Yu, B. Dong, Malignant liver tumors: treatment with percutaneous microwave ablation--complications among cohort of 1136 patients. Radiology 251(3), 933–940 (2009). https://doi.org/10.1148/radiol.2513081740 CrossRefPubMed

J. Yu, P. Liang, X.L. Yu, Z.G. Cheng, Z.Y. Han, X. Zhang, J. Dong, M.J. Mu, X. Li, X.H. Wang, US-guided percutaneous microwave ablation versus open radical nephrectomy for small renal cell carcinoma: intermediate-term results. Radiology 270(3), 880–887 (2014). https://doi.org/10.1148/radiol.13130275 CrossRefPubMed

10.

L. Sidoff, D.E. Dupuy, Clinical experiences with microwave thermal ablation of lung malignancies. Int. J. Hyperth. 33(1), 25–33 (2017). https://doi.org/10.1080/02656736.2016.1204630 CrossRef

11.

J. Xu, H. Wu, Z. Han, J. Zhang, Q. Li, J. Dou, C. An, E. Qi, J. Yu, P. Liang, Microwave ablation of benign breast tumors: a prospective study with minimum 12 months follow-up. Int. J. Hyperth. 1–9 (2018). https://doi.org/10.1080/02656736.2018.1494340

12.

X. Zhi, N. Zhao, Y. Liu, J.B. Liu, C. Teng, L. Qian, Microwave ablation compared to thyroidectomy to treat benign thyroid nodules. Int. J. Hyperth. 34(5), 644–652 (2018). https://doi.org/10.1080/02656736.2018.1456677 CrossRef

13.

B.W. Zheng, J.F. Wang, J.X. Ju, T. Wu, G. Tong, J. Ren, Efficacy and safety of cooled and uncooled microwave ablation for the treatment of benign thyroid nodules: a systematic review and meta-analysis. Endocrine 62(2), 307–317 (2018). https://doi.org/10.1007/s12020-018-1693-2 CrossRefPubMed

14.

Z. Cheng, Y. Che, S. Yu, S. Wang, D. Teng, H. Xu, J. Li, D. Sun, Z. Han, P. Liang, US-Guided Percutaneous Radiofrequency versus Microwave Ablation for Benign Thyroid Nodules: A Prospective Multicenter Study. Sci. Rep. 7(1), 9554 (2017). https://doi.org/10.1038/s41598-017-09930-7 CrossRefPubMedPubMedCentral

15.

A.P. Mainini, C. Monaco, L.C. Pescatori, C. De Angelis, F. Sardanelli, L.M. Sconfienza, G. Mauri, Image-guided thermal ablation of benign thyroid nodules. J. Ultrasound 20(1), 11–22 (2017). https://doi.org/10.1007/s40477-016-0221-6 CrossRefPubMed

16.

W. Yue, S. Wang, S. Yu, B. Wang, Ultrasound-guided percutaneous microwave ablation of solitary T1N0M0 papillary thyroid microcarcinoma: initial experience. Int. J. Hyperth. 30(2), 150–157 (2014). https://doi.org/10.3109/02656736.2014.885590 CrossRef

17.

D. Teng, G. Sui, C. Liu, Y. Wang, Y. Xia, H. Wang, Long-term efficacy of ultrasound-guided low power microwave ablation for the treatment of primary papillary thyroid microcarcinoma: a 3-year follow-up study. J. Cancer Res. Clin. Oncol. 144(4), 771–779 (2018). https://doi.org/10.1007/s00432-018-2607-7 CrossRefPubMed

18.

J. Li, Y. Liu, J. Liu, L. Qian, Ultrasound-guided percutaneous microwave ablation versus surgery for papillary thyroid microcarcinoma. Int. J. Hyperth. 34(5), 653–659 (2018). https://doi.org/10.1080/02656736.2018.1453092 CrossRef

19.

D. Teng, L. Ding, Y. Wang, C. Liu, Y. Xia, H. Wang, Safety and efficiency of ultrasound-guided low power microwave ablation in the treatment of cervical metastatic lymph node from papillary thyroid carcinoma: a mean of 32 months follow-up study. Endocrine 62(3), 648–654 (2018). https://doi.org/10.1007/s12020-018-1711-4 CrossRefPubMed

20.

J.H. Kim, J.H. Baek, H.K. Lim, H.S. Ahn, S.M. Baek, Y.J. Choi, Y.J. Choi, S.R. Chung, E.J. Ha, S.Y. Hahn, S.L. Jung, D.S. Kim, S.J. Kim, Y.K. Kim, C.Y. Lee, J.H. Lee, K.H. Lee, Y.H. Lee, J.S. Park, H. Park, J.H. Shin, C.H. Suh, J.Y. Sung, J.S. Sim, I. Youn, M. Choi, D.G. Na, 2017 Thyroid Radiofrequency Ablation Guideline: Korean Society of Thyroid Radiology. Korean J. Radiol. 19(4), 632–655 (2018). https://doi.org/10.3348/kjr.2018.19.4.632 CrossRefPubMedPubMedCentral

21.

Y. Guang, Y. Luo, Y. Zhang, M. Zhang, N. Li, Y. Zhang, J. Tang, Efficacy and safety of percutaneous ultrasound guided radiofrequency ablation for treating cervical metastatic lymph nodes from papillary thyroid carcinoma. J. Cancer Res. Clin. Oncol. 143(8), 1555–1562 (2017). https://doi.org/10.1007/s00432-017-2386-6 CrossRefPubMed

22.

G. Mauri, L. Cova, T. Ierace, A. Baroli, E. Di Mauro, C.M. Pacella, S.N. Goldberg, L. Solbiati, Treatment of metastatic lymph nodes in the neck from papillary thyroid carcinoma with percutaneous laser ablation. Cardiovasc. Interv. Radiol. 39(7), 1023–1030 (2016). https://doi.org/10.1007/s00270-016-1313-6 CrossRef

23.

W. Zhou, S. Jiang, W. Zhan, J. Zhou, S. Xu, L. Zhang, Ultrasound-guided percutaneous laser ablation of unifocal T1N0M0 papillary thyroid microcarcinoma: preliminary results. Eur. Radiol. 27(7), 2934–2940 (2017). https://doi.org/10.1007/s00330-016-4610-1 CrossRefPubMed

24.

L. Zhang, W. Zhou, W. Zhan, Y. Peng, S. Jiang, S. Xu, Percutaneous laser ablation of unifocal papillary thyroid microcarcinoma: utility of conventional ultrasound and contrast-enhanced ultrasound in assessing local therapeutic response. World J. Surg. 42(8), 2476–2484 (2018). https://doi.org/10.1007/s00268-018-4500-6 CrossRefPubMed

25.

R. Valcavi, S. Piana, G.S. Bortolan, R. Lai, V. Barbieri, R. Negro, Ultrasound-guided percutaneous laser ablation of papillary thyroid microcarcinoma: a feasibility study on three cases with pathological and immunohistochemical evaluation. Thyroid 23(12), 1578–1582 (2013). https://doi.org/10.1089/thy.2013.0279 CrossRefPubMed

26.

E. Papini, R. Guglielmi, H. Gharib, I. Misischi, F. Graziano, M. Chianelli, A. Crescenzi, A. Bianchini, D. Valle, G. Bizzarri, Ultrasound-guided laser ablation of incidental papillary thyroid microcarcinoma: a potential therapeutic approach in patients at surgical risk. Thyroid 21(8), 917–920 (2011). https://doi.org/10.1089/thy.2010.0447 CrossRefPubMedPubMedCentral

27.

J.H. Kim, J.H. Baek, J.Y. Sung, H.S. Min, K.W. Kim, J.H. Hah, D.J. Park, K.H. Kim, B.Y. Cho, D.G. Na, Radiofrequency ablation of low-risk small papillary thyroidcarcinoma: preliminary results for patients ineligible for surgery. Int. J. Hyperth., 1–11 (2016). https://doi.org/10.1080/02656736.2016.1230893

28.

M. Zhang, Y. Luo, Y. Zhang, J. Tang, Efficacy and safety of ultrasound-guided radiofrequency ablation for treating low-risk papillary thyroid microcarcinoma: a prospective study. Thyroid 26(11), 1581–1587 (2016). https://doi.org/10.1089/thy.2015.0471 CrossRefPubMed

29.

D.G. Na, J.H. Lee, S.L. Jung, J.H. Kim, J.Y. Sung, J.H. Shin, E.K. Kim, J.H. Lee, D.W. Kim, J.S. Park, K.S. Kim, S.M. Baek, Y. Lee, S. Chong, J.S. Sim, J.Y. Huh, J.I. Bae, K.T. Kim, S.Y. Han, M.Y. Bae, Y.S. Kim, J.H. Baek, Radiofrequency ablation of benign Thyroid nodules and recurrent Thyroid cancers: Consensus statement and recommendations. Kor. J. Radiol. 13(2), 117–125 (2012). https://doi.org/10.3348/kjr.2012.13.2.117 CrossRef

30.

B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26(1), 1–133 (2016). https://doi.org/10.1089/thy.2015.0020 CrossRefPubMedPubMedCentral

Titel: Preliminary report of microwave ablation for the primary papillary thyroid microcarcinoma: a large-cohort of 185 patients feasibility study
verfasst von: Deng-Ke Teng
He-Qun Li
Guo-Qing Sui
Yuan-Qiang Lin
Qiang Luo
Ping Fu
Jia-Rui Du
Chun-Xiang Jin
Hui Wang
Publikationsdatum: 15.02.2019
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 1/2019
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-019-01868-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Excess mortality after craniopharyngioma treatment: are we making progress?

Topographical factors guiding the surgical treatment of pituicytomas

Acromegaly can be cured by first-line pasireotide treatment?

Primary hyperparathyroidism due to ectopic parathyroid adenoma in an adolescent: a case report and review of the literature

Novel PET tracers: added value for endocrine disorders